(Q36114508)

English

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

2 October 2019

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

antineoplastic antimetabolite

1 reference

2 October 2019

pancreatic neoplasm

1 reference

2 October 2019

1 reference

PubMed publication ID

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

D D Von Hoff

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A L Goodwin

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

L Garcia

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 January 1998

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

5 references

Europe PubMed Central

PMC publication ID

12 August 2017

21 March 2019

24 March 2019

3 April 2019

2 October 2019

78 Suppl 3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

9-13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Chemotherapy in pancreatic cancer: a rational pursuit?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 October 2017

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

2 July 2018

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062801

23 September 2018

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer: how can we progress?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should further studies of chemotherapy be carried out in pancreatic cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/9717985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1998.748

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36114508&oldid=2198218995"